Brief: Mesoblast Says FDA Acknowledges Effects On Pain Intensity Favor Rexlemestrocel-L
19/01/2026 24:04
Jan 18 (Reuters) - Mesoblast Ltd MSB.AX: FDA ACKNOWLEDGES EFFECTS ON PAIN INTENSITY FAVOR REXLEMESTROCEL-L, CONFIRMS 12-MONTH REDUCTION IN BACK PAIN SUPPORTS PRODUCT EFFICACY MESOBLAST LTD - SECOND PHASE 3 TRIAL MSB-DR004 OVER 50% ENROLLED MESOBLAST LTD - SIGNIFICANT PAIN REDUCTION AND OPIOID CESSATION IN PHASE 3 TRIAL MESOBLAST LTD - REXLEMESTROCEL-L RECEIVES RMAT DESIGNATION FROM FDA Source text: ID:nGNX1Qh23k Further company coverage: MSB.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mesoblast
See all newsBrief: Mesoblast William Burns To Retire From Board At 2026 AGM
Brief: Mesoblast Says Q1 Net Revenues Up 44%
Australia's Mesoblast hits one-month high on upbeat quarterly update
Australia's Mesoblast drops as Bell Potter cuts target price after key drug misses sales view
Brief: Mesoblast Says FDA Approves New Potency Assay For Commercial Ryoncil